GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectar Biosciences Inc (NAS:CLRB) » Definitions » Market Cap

Cellectar Biosciences (Cellectar Biosciences) Market Cap : $97.43 Mil (As of Apr. 25, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Cellectar Biosciences Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Cellectar Biosciences's share price for the quarter that ended in Dec. 2023 was $2.77. Cellectar Biosciences's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 20.74 Mil. Therefore, Cellectar Biosciences's market cap for the quarter that ended in Dec. 2023 was $57.46 Mil.

Cellectar Biosciences's quarterly market cap increased from Jun. 2023 ($18.99 Mil) to Sep. 2023 ($26.18 Mil) and increased from Sep. 2023 ($26.18 Mil) to Dec. 2023 ($57.46 Mil).

Cellectar Biosciences's annual market cap declined from Dec. 2021 ($40.57 Mil) to Dec. 2022 ($16.05 Mil) but then increased from Dec. 2022 ($16.05 Mil) to Dec. 2023 ($57.46 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Cellectar Biosciences's Enterprise Value for Today is $95.77 Mil.


Cellectar Biosciences Market Cap Historical Data

The historical data trend for Cellectar Biosciences's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectar Biosciences Market Cap Chart

Cellectar Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.12 94.52 40.57 16.05 57.46

Cellectar Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.05 13.93 18.99 26.18 57.46

Competitive Comparison of Cellectar Biosciences's Market Cap

For the Biotechnology subindustry, Cellectar Biosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectar Biosciences's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectar Biosciences's Market Cap distribution charts can be found below:

* The bar in red indicates where Cellectar Biosciences's Market Cap falls into.



Cellectar Biosciences Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Cellectar Biosciences's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$2.77*20.7441
=$57.46

Cellectar Biosciences's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )=Share Price (Q: Dec. 2023 )*Shares Outstanding (EOP) (Q: Dec. 2023 )
=$2.77*20.7441
=$57.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cellectar Biosciences  (NAS:CLRB) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Cellectar Biosciences Market Cap Related Terms

Thank you for viewing the detailed overview of Cellectar Biosciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectar Biosciences (Cellectar Biosciences) Business Description

Traded in Other Exchanges
Address
100 Campus Drive, Florham Park, NJ, USA, 07932
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
Executives
Andrei Shustov officer: Senior Vice President, Medical 7 PARKLAND DRIVE, MILFORD NJ 08848
Darrell Shane Lea officer: Chief Commercial Officer 7 PARKLAND DRIVE, MILFORD NJ 08848
Chad J Kolean officer: Chief Financial Officer C/O CELLECTAR BIOSCIENCES, INC., 3301 AGRICULTURE DRIVE, MADISON WI 53716
Douglas J Swirsky director C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Frederick W Driscoll director
Asher Chanan-khan director C/O CELLECTAR BISCIENCES, INC., 100 CAMPUS DRIVE NJ 07932
James V Caruso director, officer: President and CEO C/O CELLECTAR BIOSCIENCES, INC., 8383 GREENWAY BLVD STE 600, MIDDLETON WI 53562
Dov Elefant officer: Chief Financial Officer EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Jarrod Longcor officer: Chief Business Officer C/O RIB-X PHARMACEUTICALS, INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511
Friend John E. Ii officer: VP, Chief Medical Officer 26 ORCHARD LANE, COLT NECK NJ 07722
John Neis director 505 S. ROSA ROAD, SUITE 201, MADISON WI 53719
Stefan Loren director 3226 AVENIDA DE SUENO, CARLSBAD CA 92009
Stephen A Hill director 50 AVENUE GENERAL DE GAULLE, BRUXELLES C9 9999999999
Igor D Grachev officer: Chief Medical Officer 15 REID LANE, MILLSTONE TWP NJ 08535
Bernhardt Charles Thomas Iii officer: Interim CFO 23 BIRCH ROAD, MALVERN PA 19355